Centrient Pharmaceuticals to acquire Astral SteriTech, expanding its product portfolio with sterile injectable antibiotic finished dosage forms

Centrient Pharmaceuticals, the business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins and anti-fungals, today announced the signing of an agreement for the acquisition of Astral SteriTech Private Limited, a leading international manufacturer specialised in sterile antibiotic injectable finished dosage forms. With the acquisition of Astral SteriTech, Centrient strengthens its position as the global business-to-business industry leader in beta-lactam antibiotics.

Centrient Pharmaceuticals recieves 2020 Gold Sustainability Rating

Our Sustainability Report 2019

Sustainability matters a great deal to everyone at Centrient Pharmaceuticals, it is core to our mission and essential in shaping our authentic and purposeful culture.

Centrient Pharmaceuticals donating 30,000 masks to support healthcare workers in hospitals in the Netherlands and Barcelona, Spain

Centrient Pharmaceuticals appoints Rex Clements as Chief Executive Officer after Karl Rotthier decides to step down from the role

Centrient Pharmaceuticals, the global leader in the production and commercialisation of sustainable antibiotics, next-generation statins and anti-fungals, is announcing that Karl Rotthier has decided to step down as CEO after having built a highly successful company over the last ten years and managing a smooth transition to the new ownership under Bain Capital.